This website uses cookies to improve your experience. Learn more about cookies and how to manage them.

Dr Malcolm Boyce BSc (Physiol) MD FRCP FFPM

Dr Malcolm Boyce BSc (Physiol)  MD  FRCP  FFPM

Name:

Dr Malcolm Boyce BSc (Physiol) MD FRCP FFPM HonFBPhS

Organisation:

Hammersmith Medicines Research Ltd and Trio Medicines Ltd

Year elected:

2019

Affinity Group(s):

  • Drug Discovery, Development and Evaluation

Primary professional setting:

Clinical

I’m the Medical and Managing Director of HMR, a Clinical Research Organisation that specialises in clinical pharmacology studies for the pharmaceutical industry. HMR has 270 staff, and its own purpose-built premises with 145 beds, and on-site pharmacy and laboratory. We’ve done over 870 early clinical trials since 1993. I’ve held various posts in clinical and academic medicine, and I’ve worked for several of the major pharmaceutical companies, during which time I carried out or co-ordinated numerous clinical trials worldwide across all phases of drug development with a variety of new compounds. I’m also CEO of a pharmaceutical company, Trio Medicines, a subsidiary of HMR, that has a portfolio of novel compounds at various stages of development. I’m Honorary Professor of Clinical Pharmacology, Queen Mary University of London, and Visiting Professor of Clinical Pharmacology, King’s College, London. I’ve written and co-authored over 160 publications on drug development and research ethics